ARTES attends Biofit 2017

Meet us at the Biofit 2017 tak­ing place in Stras­bourg Novem­ber 28 -29. Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing and we are present with our own booth (num­ber F2). Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem. We look for­ward to meet­ing you!

www.biofit-event.com

ARTES receives French Research Tax Credit (CIR) Accreditation

ARTES Biotech­nol­o­gy GmbH today announced that it has just obtained gov­ern­men­tal approval for ‘Crédit d’Impôt Recherche’ (CIR) for a three-year peri­od from the French Min­istry of High­er Edu­ca­tion and Research (MESR).

The French R&D tax cred­it CIR gives French com­pa­nies the abil­i­ty to claim tax relief on 30% on all gen­er­at­ed costs out­sourced to ARTES’ R&D ser­vices.
“We are pleased to receive this accred­i­ta­tion and to be approved as valid and reli­able R&D provider from the French Min­istry”, Dr Michael Pio­ntek, Man­ag­ing Direc­tor of ARTES. “It allows our cus­tomers in France to ben­e­fit from tax relief of their R&D expens­es com­mit­ted to us and it will help us to tie up our rela­tion­ships with our present clients in France and to install new col­lab­o­ra­tions”.

ARTES Biotech­nol­o­gy is glob­al­ly active as R&D com­pa­ny spe­cial­ized in devel­op­ing bio­phar­ma­ceu­ti­cal and vac­cine pro­duc­tion process­es.
The com­pa­ny oper­ates world­wide from its 850m2 S1 facil­i­ties in Lan­gen­feld, from where it also offers cell line engi­neer­ing based on yeast (Hansenu­la poly­mor­pha) and bac­te­r­i­al (E. coli and Bacil­lus) expres­sion plat­forms, lab scale up- and down­stream process devel­op­ment, sup­ply of non-GMP bulk mate­r­i­al (API) for activ­i­ty and tox­i­c­i­ty tests and tech­nol­o­gy trans­fer to cGMP facil­i­ties and scale-up sup­port.

ARTES was part of a successful international consortium

EU Research Project Nano3Bio sums up:
Promis­ing achieve­ments for win­ning future raw mate­ri­als

Since fos­sil raw mate­ri­als are rapid­ly run­ning out, their sub­sti­tu­tion by renew­able resources is becom­ing increas­ing­ly impor­tant. In this process, the bio­log­i­cal pro­duc­tion of raw mate­ri­als will have to play a lead­ing role. The inter­na­tion­al project Nano3Bio, includ­ing ARTES Biotech­nol­o­gy has con­tributed to mas­ter this chal­lenge. Nano3Bio’s main goal was the biotech­no­log­i­cal pro­duc­tion of so-called chi­tosans, which can be used as raw mate­ri­als for med­i­cine, agri­cul­ture, cos­met­ics and oth­er appli­ca­tion fields. The Euro­pean Com­mis­sion sup­port­ed the research project with almost nine mil­lion Euros over the past four years. Recent­ly, the con­sor­tium held its final con­fer­ence ‘The Future of Chi­tosans’ in Hyder­abad, India.
“We’re proud of Nano3Bio’s out­comes. In impor­tant fields, the con­sor­tium achieved or pre­pared break­throughs from basic research to biotech­no­log­i­cal appli­ca­tions”, says Pro­fes­sor Dr. Bruno Moer­schbach­er, biol­o­gist at the Uni­ver­si­ty of Mün­ster and coor­di­na­tor of the project.

More about Nano3Bio and on the future of chi­tosans: www.nano3bio.eu

ARTES received next grant of patent for METAVAX®

ARTES is pleased to announce a new EU based grant of patent for their well-proven virus-like-par­ti­cle (VLP) tech­nol­o­gy plat­form METAVAX®.

The new patent inte­grates exact­ly in our exist­ing patent port­fo­lio and will fur­ther strength­en our tech­nol­o­gy offer”, said Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES. “In com­bi­na­tion with our pro­pri­etary yeast expres­sion tech­nol­o­gy our anti­gen pre­sen­ta­tion plat­form METAVAX® is an excel­lent and unique tool for the devel­op­ment of effec­tive, safe and afford­able vac­cines.”

Cur­rent­ly, the plat­form METAVAX® is used in sev­er­al clients’ projects as well as in sev­er­al in-house research projects. With­in the “Pluri­vax” project, fund­ed by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) as part of the 8th Euro­Trans­Bio call, ARTES enhances its VLP based vac­cine plat­form METAVAX® and devel­ops process­es espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions.

Our intel­lec­tu­al prop­er­ty strat­e­gy is to pro­vide mul­ti­ple lay­ers of pro­tec­tion for our tech­nol­o­gy plat­form port­fo­lio. With this new patent, we have addi­tion­al rein­force­ment to our exist­ing patent estate,” said Dr. Melanie Pio­ntek.

ARTES joins WAVESCATTER

A con­sor­tium of 5 com­pa­nies and the Fraun­hofer-Insti­tut für Lasertech­nik ILT, aim to devel­op under the name of WAVESCATTER („Winke­lau­flösende Wellen­leit­er-Streulicht­sonde für die Inline-Prozes­s­an­a­lytik“) a new kind of scat­tered light sen­sor for pre­cise inline par­ti­cle ana­lyt­ic.

The project will be fund­ed for a three year peri­od by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) in the pro­gram Dig­i­tale Optik«.

Part­ner of the con­sor­tium are:

  • Hell­ma GmbH & Co. KG, Müll­heim (Kon­sor­tialführer)
  • ABS Gesellschaft für Automa­tisierung, Bild­ver­ar­beitung und Soft­ware mbH, Jena
  • ARTES Biotech­nol­o­gy GmbH, Lan­gen­feld (Rhein­land)
  • Light­Fab GmbH, Aachen
  • HiTec Zang GmbH, Her­zo­gen­rath.

 

PR in Ger­man lan­guage:

Mit Photonen im Trüben messen

Vielfältige chemis­che und biotech­nol­o­gis­che Prozesse sind mit dem Entste­hen, dem Wach­s­tum oder der Verän­derung von Par­tikeln ver­bun­den. Eine detail­lierte Beobach­tung von Par­tikel­größe und Par­tike­lan­zahl im laufend­en Prozess ohne zeit- und arbeit­saufwändi­ge Probe­nent­nahme soll die Überwachung und Steuerung solch­er Prozesse in Echtzeit zukün­ftig vere­in­fachen oder über­haupt erst ermöglichen. Im Pro­jekt »WAVESCATTER« haben sich dazu vier Unternehmen und das Fraun­hofer-Insti­tut für Lasertech­nik ILT zusam­mengeschlossen. Ziel ist die Entwick­lung ein­er winke­lau­flösenden Wellen­leit­er-Streulicht­sonde für die präzise Inline-Par­tike­l­an­a­lytik.

Wirk­stoffe für Medika­mente wer­den heute zum großen Teil durch spezielle Mikroor­gan­is­men in Biore­ak­toren pro­duziert, wo die Wach­s­tum­sprozesse von beson­der­er Bedeu­tung sind. Die Mikrobenkul­tur wird zusam­men mit ein­er geeigneten Nährlö­sung in den Biore­ak­tor gebracht, ver­mehrt sich dort und pro­duziert die gewün­schte Sub­stanz wie z.B. Insulin, den Leben­sret­ter für Dia­betik­er. Die Mikrobenkul­tur im Biore­ak­tor darf auf keinen Fall mit anderen Mikroor­gan­is­men verun­reinigt wer­den. Dies gelingt am besten, wenn der Reak­tor her­metisch abgeschlossen wird, bis der Pro­duk­tion­sprozess been­det ist. Die Her­aus­forderung liegt in der ständi­gen Überwachung des Prozess­es für einen opti­malen Ablauf, um beispiel­sweise die Nährstof­fzu­gabe an das Wach­s­tumsver­hal­ten der Mikroor­gan­is­men anzu­passen. Eine regelmäßige Proben­nahme mit nach­fol­gen­der Offline-Analyse der Mikrobenkul­tur ist nicht nur arbeits- und zeit­in­ten­siv, son­dern stellt auch eine mögliche Kon­t­a­m­i­na­tion­squelle für den Biore­ak­tor dar. Bis­lang wer­den Proben aus dem Reak­tor ent­nom­men und verdün­nt, um z.B. die Größen­verteilung und Anzahldichte der Mikroor­gan­is­men messen zu kön­nen. Mit der im WAVESCATTER Pro­jekt anvisierten Tech­nolo­gie wird eine inline-fähige Par­tike­l­an­a­lytik entwick­elt, die ohne Proben­verdün­nung auch in optisch dicht­en Lösun­gen Par­tikel­größen zwis­chen weni­gen 10 nm und mehreren µm in Echtzeit bes­timm­bar macht. Dadurch wer­den völ­lig neue Möglichkeit­en zur rück­gekop­pel­ten Überwachung und Steuerung von chemis­chen und biotech­nol­o­gis­chen Pro­duk­tion­sprozessen ermöglicht. Eine Kon­t­a­m­i­na­tion des Fer­menters durch uner­wün­schte Frem­dor­gan­is­men kann frühzeit­ig erkan­nt wer­den. Qual­itätssicherung und Prozes­saus­beute kön­nen so verbessert wer­den. Damit die Probe­nent­nahme aus einem Biore­ak­tor nicht mehr notwendig ist, hat sich das Kon­sor­tium in diesem Ver­bund­pro­jekt zusam­menge­fun­den. Ziel ist die Entwick­lung ein­er optis­chen Tauch­sonde, welch­er durch eine winke­laufgelöste Streulichtmes­sung die Größen­verteilung von Par­tikeln z.B. in Biofer­mentern bes­tim­men kann. Die Licht­führung in der Sonde erfol­gt mit Hil­fe von Wellen­leit­ern, die Licht­de­tek­tion mit ein­er CCD / CMOS Zeile. Aus dem winke­laufgelösten Streulichtsig­nal kön­nen über die Par­tikel­größen­verteilung Infor­ma­tio­nen zu Zell­größe und Teilchen­zahldichte im Inneren des Biore­ak­tors gewon­nen und zur Prozesss­teuerung ver­wen­det wer­den. Eine Fremdbe­siedelung durch uner­wün­schte Mikroor­gan­is­men kann frühzeit­ig erkan­nt wer­den. Per­spek­tivisch ist auch die Ermit­tlung von wichti­gen zell­bi­ol­o­gis­chen Para­me­tern möglich (Lebend- / Totzel­lun­ter­schei­dung, Erken­nung von intrazel­lulären Inklu­sion­skör­pern).

Nach erfol­gre­ichem Pro­jek­tab­schluss ste­ht der Prozes­s­an­a­lytik in den Bere­ichen Arzneimit­tel­her­stel­lung und Lebens­mit­tel­pro­duk­tion ein neues Werkzeug zur Ver­fü­gung, mit dem Prozess­pa­ra­me­ter ein­fach­er, flex­i­bler und umfassender in Echtzeit und ohne Probe­nahme erfasst wer­den kön­nen. Weit­ere Ein­satzge­bi­ete kön­nen chemis­che Poly­meri­sa­tion­sreak­tio­nen, Kristalli­sa­tio­nen oder Dis­per­sion­sprozesse sein.

Das Pro­jekt „Winke­lau­flösende Wellen­leit­er-Streulicht­sonde für die Inline-Prozes­s­an­a­lytik — WAVESCATTER“ wird vom BMBF im Rah­men der Pho­tonik Forschung Deutsch­land, Förderini­tia­tive »Dig­i­tale Optik«, unter dem Förderkennze­ichen 13N14176 mit ins­ge­samt 2,1 Mio € gefördert.

BIO International Convention 2017

Meet us at the BIO Inter­na­tion­al Con­ven­tion tak­ing place in San Diego, CA, USA  June 19 -22.

Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem.

We look for­ward to meet­ing you!

 

www.convention.bio.org/2017

15 Years ARTES Biotechnology

Toady, ARTES has 15 year anniver­sary. In 2002 at May 10th Michael Pio­ntek found­ed ARTES as R&D com­pa­ny, spe­cial­ized in devel­op­ing yeast cell lines for recom­bi­nant pro­tein pro­duc­tion. In 15 years ARTES has posi­tioned itself as val­ued part­ner for the phar­ma­ceu­ti­cal and life sci­ence indus­try and it is now spe­cial­ized in devel­op­ing whole biotech­nol­o­gy pro­duc­tion process­es.

ARTES attends European Animal Health Investment Forum

ARTES will head for London’s elite May­fair dis­trict in Feb­ru­ary to take part in the ‘Drag­ons Den’ of vet­eri­nary med­i­cine, the Euro­pean Ani­mal Health Invest­ment Forum.

This will be ARTES’ first par­tic­i­pa­tion in the high pres­tige invest­ment net­work­ing event.

ARTES will be rep­re­sent­ed by its Man­ag­ing Direc­tor, Dr. Michael Pio­ntek, who will be talk­ing in par­tic­u­lar about the devel­op­ment of its inno­v­a­tive pro­pri­etary vac­cine devel­op­ment plat­form, METAVAX®.

METAVAX®advantages

METAVAX® gen­er­ates vac­cines based on the WHO-rec­om­mend­ed yeast organ­ism Hansenu­la poly­mor­pha.

ARTES Biotech­nol­o­gy also has exper­tise in human and ani­mal vac­cine devel­op­ment and is col­lab­o­rat­ing with ani­mal health leader Boehringer Ingel­heim to devel­op  a vac­cine based on Hansenu­la poly­mor­pha expres­sion, com­bined with the METAVAX® plat­form

Self-adjuvanting vaccines

We look for­ward to attend­ing the Euro­pean Ani­mal Health Invest­ment Forum for the oppor­tu­ni­ty to net­work with CEOs, busi­ness devel­op­ers and sci­en­tists from vet­eri­nary phar­ma­ceu­ti­cal com­pa­nies inter­est­ed in devel­op­ment of high­ly immuno­genic vac­cines,” com­ment­ed Dr. Pio­ntek.

This is a great oppor­tu­ni­ty to find new con­tacts, refresh old ones and show how we have devel­oped an eco­nom­i­cal approach for low-cost mass pro­duc­tion of safe, effec­tive and self-adju­vant­i­ng vac­cines,” said Dr. Pio­ntek.

ARTES will also use the meet­ing to share knowl­edge about its VLP tech­nol­o­gy for anti­gen pre­sen­ta­tion and oth­er vac­cine tech­nolo­gies.  It will also exchange infor­ma­tion on its spe­cial­ist cell lines and process devel­op­ment for bio-phar­ma­ceu­ti­cal prod­ucts.

Meet us at the Ani­mal Health Invest­ment in Lon­don, 22nd and 23rd Feb­ru­ary, at the Mil­len­ni­um Lon­don May­fair Hotel or con­tact us pre­vi­ous­ly for a per­son­al meet­ing! We look for­ward to meet­ing you!

ARTES and BioSun announce co-development for HPV vaccine

Lan­gen­feld, Ger­many / Tehran, Iran  

ARTES Biotech­nol­o­gy and Bio­Sun Pharmed announced to join forces for the devel­op­ment and man­u­fac­tur­ing of a HPV (human papil­lo­ma virus) vac­cine in Iran.

The agreed long-term col­lab­o­ra­tion involved the strength of both part­ners. ARTES Biotech­nol­o­gy GmbH (ARTES) is spe­cial­ized in cell line and process devel­op­ment of virus like par­ti­cle (VLP) based vac­cines and in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal­ly rel­e­vant pro­duc­tion process­es.

Bio­Sun Pharmed Co is involved in the man­u­fac­tur­ing of high qual­i­ty and safe vac­cines and bio­phar­ma­ceu­ti­cal prod­ucts for the domes­tic and inter­na­tion­al mar­kets.

Human papil­lo­ma virus infec­tion (HPV) is the most com­mon sex­u­al­ly trans­mit­ted infec­tion glob­al­ly. Most peo­ple are infect­ed at some point in their lives. There are approx­i­mate­ly 79 mil­lion men/women active­ly infect­ed with the virus at any point in time. Annu­al­ly, there are 14 mil­lion new­ly diag­nosed cas­es of HPV. HPV infec­tion can cause in warts or pre­can­cer­ous lesions. The pre­can­cer­ous lesions increase the risk of can­cer.

In 2012, about 270,000 women died from cer­vi­cal can­cer, more than 85% of these deaths occur­ring in low and mid­dle income coun­tries.

We are extreme­ly delight­ed about the mutu­al­ly agreed col­lab­o­ra­tion. This agree­ment is the next step in ARTES’ strat­e­gy to devel­op from a ser­vice provider for process devel­op­ment to a part­ner for full phar­ma­ceu­ti­cal prod­uct devel­op­ment,” Dr. Michael Pio­ntek, founder and man­ag­ing direc­tor of ARTES Biotech­nol­o­gy.

For the first time, ARTES will be respon­si­ble for process devel­op­ment of API, for­mu­la­tion, qual­i­ty con­trol and sup­ply of pre­clin­i­cal test mate­r­i­al. In addi­tion, ARTES will be engaged in design of the man­u­fac­tur­ing site at Bio­Sun and in selec­tion of third par­ties for GMP man­u­fac­tur­ing.

I am real­ly pleased that after tech­ni­cal and com­mer­cial dis­cus­sions, we could final­ly make col­lab­o­ra­tion agree­ment with a well-known and reli­able part­ner for not only pro­duc­ing pre-mas­ter cell banks but also for co-devel­op­ments of our mutu­al inter­est­ed prod­ucts. Our mis­sion is pro­duc­ing high qual­i­ty and afford­able vac­cines and biotech prod­ucts improv­ing health lev­el of com­mu­ni­ty.” Dr. Moham­mad Tagha­vian, man­ag­ing direc­tor of Bio­sun Pharmed.

Finan­cial details of this agree­ment were not dis­closed.

Sun Pharma & ICGEB sign exclusive deal on dengue vaccine — ARTES adds experience in VLP development and production

NEW DELHI, India I Octo­ber 19, 2016

Inter­na­tion­al Cen­tre for Genet­ic Engi­neer­ing and Biotech­nol­o­gy (ICGEB) and Sun Phar­ma today announced their new col­lab­o­ra­tion for devel­op­ment of a dengue vac­cine, tar­get­ed against all the four serotypes of Dengue virus that cause dis­ease in humans. ICGEB has devel­oped a tai­lored recom­bi­nant virus-like-par­ti­cle (VLP) based tetrava­lent dengue vac­cine, con­tain­ing host-recep­tor bind­ing domain of enve­lope pro­tein of all the four DENV serotypes. ICGEB has con­duct­ed pre-clin­i­cal stud­ies over the past sev­en years and devel­oped the exist­ing Know-How and Patents for this dengue vac­cine can­di­date.

Sun Phar­ma invests over US$ 300 mil­lion annu­al­ly on research and devel­op­ment in phar­ma­ceu­ti­cals and bio­log­ics. The Com­pa­ny will use its in-house exper­tise as well as exper­tise of its Asso­ciate com­pa­ny, ARTES Biotech­nol­o­gy GmbH, in devel­op­ment of dengue vac­cine. ARTES will add their expe­ri­ence and pro­pri­etary know-how in pro­duc­tion of VLP based vac­cines from yeast pro­duc­tion cell lines. Hep-B and HPV vac­cines devel­oped by ARTES are licensed to sev­er­al com­pa­nies world­wide and a Malar­ia vac­cine pro­gram is spon­sored by PATH (Malar­ia Vac­cine Ini­tia­tive). Tak­en togeth­er, the Com­pa­ny has past expe­ri­ence in devel­op­ment of Hep-B and Typhoid vac­cines, as well as com­plex vac­cines, such as HPV and Malar­ia.

 

For the full text, see: http://www.sunpharma.com/media/press-releases